RAD51 and leukemia: Combining treatment with DOCK2 knockdown and DDR inhibitors such as CHK1 inhibitor MK876, WEE1 inhibitor MK1775, and RAD51 inhibitor 1302 significantly enhanced the sensitivity of mice with FLT3-ITD mutant leukemia cells to cytarabine (Wu et al., 2019).